2,849 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, HoldingsChannel reports. The firm bought 2,849 shares of the biopharmaceutical company’s stock, valued at approximately $163,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Congress Asset Management Co. raised its position in shares of Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after buying an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB raised its position in Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares in the last quarter. American Century Companies Inc. lifted its stake in Halozyme Therapeutics by 9.7% during the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock worth $43,002,000 after purchasing an additional 72,544 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Halozyme Therapeutics by 37.8% in the 2nd quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock worth $36,449,000 after purchasing an additional 191,030 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total value of $590,900.00. Following the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $39,988,802.96. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 60,000 shares of company stock worth $3,425,000 in the last 90 days. Company insiders own 2.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HALO shares. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Finally, Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $48.47 on Thursday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company has a 50-day moving average price of $54.00 and a 200-day moving average price of $53.71. The company has a market cap of $6.17 billion, a price-to-earnings ratio of 16.05, a price-to-earnings-growth ratio of 0.43 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.